Kopran Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹172Cr
- −7.4% YoY
- +3.7% QoQ
- Net profit
- ₹10Cr
- −48% YoY
- −6.9% QoQ
- Margin
- 9.92%
- −1.7 pp YoY
- −2 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Kopran Ltd Q4 FY25 key numbers
- Revenue
- Year-on-Year Change in Quarterly Revenue: Decrease of Rs. 1,372 Lakhs (~7.37% decline).
As stated in Kopran Ltd's Q4 FY25 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Kopran Ltd's Q4 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q4 FY 2024-25 Revenue from Operations: Rs. 17,236 Lakhs. Q4 FY 2024-25 Financials (Page 5):.
From Kopran Ltd's Q4 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4 FY 2024-25 Revenue from Operations: Rs. 17,236 Lakhs
- Q4 FY 2023-24 Revenue from Operations: Rs. 18,608 Lakhs
- Year-on-Year Change in Quarterly Revenue: Decrease of Rs. 1,372 Lakhs (~7.37% decline)
- Q4 FY 2024-25 Formulations Revenue: Rs.
- Q4 FY 2024-25 APIs Revenue: Rs.
- FY 2024-25 Total Sales/Other Income: Rs. 63,359 Lakhs
2 more points from Kopran Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Kopran Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Focus on capacity expansion is highlighted as a strategic imperative (Page 15).
- Setting up of an API and R&D facility at Panoli is mentioned as part of growth strategy (Page 15).
- Emphasis on capacity expansion is aligned with developing high-value/high-volume APIs and intermediates (Page 15).
- Commitment to compliance with global regulatory standards for all plants is noted but without specific project details (Page 16).
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Kopran Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Kopran Ltd said on order book & pipeline — free account, 30 seconds.
Kopran Ltd — Quarterly revenue & net profit
Kopran Ltd Q4 FY25 results — key figures
| ₹ Cr | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 172 | 186 | -7.4% | 166 | +3.7% |
| Operating profit (EBITDA) | 17 | 22 | -21.2% | 20 | -13.9% |
| Operating margin | 9.92% | 11.66% | -1.7 pp | 11.94% | -2 pp |
| Profit before tax | 14 | 25 | -45.6% | 14 | -1.1% |
| Net profit (PAT) | 10 | 19 | -48% | 10 | -6.9% |
| EPS (₹) | 2.01 | 3.86 | -47.9% | 2.16 | -6.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹211 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Kopran's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharmaceuticals (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Kopran Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Kopran Ltd Q4 FY25 results?
Q4 FY 2024-25 Revenue from Operations: Rs. 17,236 Lakhs. Q4 FY 2024-25 Financials (Page 5):.
What is Kopran Ltd share price analysis?
Kopran Ltd currently shows a neutral. The stock trades at a P/E of 53.7 with a market cap of ₹1,342 Cr. Investors should review the full earnings analysis for detailed insights.
Is Kopran Ltd planning capital expenditure?
Focus on capacity expansion is highlighted as a strategic imperative (Page 15).
Keep Kopran Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
